Latest filing published 21 Mar 2023 for Oncology Institute, Inc..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Matthew P. Miller: trading record in brief
Matthew P. Miller, listed as chief executive, appears in our data through filings on Starling Oncology, Inc. shares, published by SEC (Form 4). The record holds 7 filings, for trades running from 21 March 2022 to 17 March 2023.
Market trades split into 1 purchase (€66k) and 1 sale (€1,134). Netting one side against the other leaves €65k of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 4 share grants.
The record was last updated on 21 March 2023 with a share grant in Starling Oncology, Inc. The latest purchase dates back some time: it was published 1,421 days ago, on 20 December 2022. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Matthew P. Miller
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 67,667 shares0Common stockSEC:0001628280-23-008832:0
- 73,684 shares@ US$0.9596.7% of flowCommon StockSEC:0001799191-22-000058:0Canonical exit: 16 Mar 2023 (T+90)
- 577 shares@ US$2.02771.7% of flowCommon StockSEC:0001799191-22-000051:0
- 23,607 shares0Common StockSEC:0001799191-22-000037:0
- 577 shares@ US$2.02771.7% of flowCommon StockSEC:0001799191-22-000013:0
- 6,386 shares0Common stockSEC:0001628280-22-007095:0
6 of 6 declarations
